Objective To analyze the clinical and electrophysiological features of one geneology with limbgirdle muscular dystrophy(LGMD). Methods Twenty-seven members of one family with limb-girdle muscular dystrophy(LGMD)were investigated.Fourteen of them were examined with electromyography(EMG)and their motor conduction velocities(MCV)and sensory conduction velocities(SCV)were measured.Among them,10 had no clinical manifestations,while 4 demonstrated symptoms and signs of LGMD. Results Three of the 4 patients had suffered from LGMD when young.They demonstrated the typical clinical features,including the progressive muscle weakness in the upper and lower extremities,positive Gower signs,duck gait,muscle atrophy distributed tO the proximal extremity,and no gastrocnemius hypertrophy.One subject presented atypical characteristics.The MCVs and SCVs of the 4 patients were normal,but neuropathic manifestations were found in the EMGS of 3 of them.and mixed neuropathic and myopathic manifestations were found in the EMG of the other.Conclusion LGMD patients in the same family can vary in their clinical characteristics.The longer the duration,the more severe the clinical features.Electrophysiological examination can reveal normal MCV and SCV but abnormal elctromyography.

OBJECTIVETo investigate the effect of astragaloside IV (As IV) on the activation of rennin-angiotensin system in rats with pressure-overload induced cardiac hypertrophy.

METHODLeft ventricle hypertrophy was induced by abdominal aorta banding between bilateral renal aortas for 12 weeks. Rats were given astragaloside IV 1.0 mg x kg(-1) and 3.3 mg x kg(-1) for 12 weeks, respectively. After treatment, the left ventricular mass index (LVMI)was calculated by morphometry methods. Plasma and cardiac tissue angiotensin II, and plasma aldosterone were measured by ELISA method. Gene expressions of ACE, AT1 and AT2 in cardiac tissue were detected by real time PCR. Protein expressions of AT1 and AT2 in cardiac tissue were detected by Western blot.

RESULTCompared with model rats, LVMI was decreased by astragaloside IV treatment. Biochemical results indicated that the contents of angiotensin II in plasma and cardiac tissue as well as aldosterone in plasma were all increased in abdominal aorta banding rats comparing with sham-operated rats, then, decreased by astragaloside IV treatment. Gene expressions of cardiac ACE was downregulated by astragaloside IV, however, gene and protein expressions of cardiac AT2 were upregulated by astragaloside IV. Both elevated gene and protein expressions of AT1 were not attenuated by astragaloside IV.

CONCLUSIONExcessive activated rennin-angiotensin system in rats with pressure-overload induced cardiac hypertrophy is inhibited by astragaloside IV treatment.

Aldosterone ; blood ; Angiotensin II ; blood ; metabolism ; Animals ; Blood Pressure ; physiology ; Cardiomegaly ; drug therapy ; Enzyme-Linked Immunosorbent Assay ; Hypertrophy, Left Ventricular ; drug therapy ; metabolism ; Male ; Peptidyl-Dipeptidase A ; genetics ; Polymerase Chain Reaction ; Rats ; Rats, Sprague-Dawley ; Receptor, Angiotensin, Type 1 ; genetics ; Receptor, Angiotensin, Type 2 ; genetics ; Renin-Angiotensin System ; drug effects ; Saponins ; therapeutic use ; Triterpenes ; therapeutic use

Objective To explore the change of peripheral galectin (Gal)-3 and N-terminal B-type brain natriuretic peptide (NT-proBNP) in patients with chronic heart failure.Methods A total of 89 patients with chronic heart failure (CHF) were enrolled.Peripheral Gal-3,NT-proBNP were detected by enzyme-linked immunosorbent assay (ELISA) or Electrochemical luminescence method.The expression levels of Gal-3,NT-proBNP in patients with different kinds of heart failure and cardiac functional grading were analyzed.Results There were significant differences in expression levels of Gal-3 and NT-proBNP between patients with HFPEF and patients with HFREF.There was significant differences of Gal-3 and NT-proBNP in patients with NYHA heart function class Ⅱ,Ⅲ and Ⅳ.Gal3 was positively correlated with NT-proBNP (r =0.230,P =0.030) and negatively correlated with LVEF (r =-0.533,P =0.000).NT-proBNP was negatively correlated with LVEF (r =-0.372,P =0.000).Conclusion Peripheral Gal-3,NT-proBNP could be considered as two important markers for judging severity of illness in patients with CHF.

Objective To explore the change of peripheral galectin (Gal)-3 and N-terminal B-type brain natriuretic peptide (NT-proBNP) in patients with chronic heart failure.Methods A total of 89 patients with chronic heart failure (CHF) were enrolled.Peripheral Gal-3,NT-proBNP were detected by enzyme-linked immunosorbent assay (ELISA) or Electrochemical luminescence method.The expression levels of Gal-3,NT-proBNP in patients with different kinds of heart failure and cardiac functional grading were analyzed.Results There were significant differences in expression levels of Gal-3 and NT-proBNP between patients with HFPEF and patients with HFREF.There was significant differences of Gal-3 and NT-proBNP in patients with NYHA heart function class Ⅱ,Ⅲ and Ⅳ.Gal3 was positively correlated with NT-proBNP (r =0.230,P =0.030) and negatively correlated with LVEF (r =-0.533,P =0.000).NT-proBNP was negatively correlated with LVEF (r =-0.372,P =0.000).Conclusion Peripheral Gal-3,NT-proBNP could be considered as two important markers for judging severity of illness in patients with CHF.

? Concept analysis of expectation regarding aging (ERA) is carried out by Walker and Avant's strategy. Four defining attributes of ERA were identified including self-definition and social attributes, aging perception, degree of positive willingness to participate in the life process, confidence in adapting to the decline with aging. ERA mainly affects the health outcomes of the elderly through health promotion behaviors, activities of daily living, physical examination behaviors, the path of new-established support system,expectation regarding aging and attitudes towards aging of stakeholders.

Objective:To analyze the expression of cell division cycle associated protein 5 (CDCA5) in pancreatic cancer tissues and its correlation with prognosis based on the bioinformatics.Methods:The RNA sequencing data (HTSeq-FPKM) and corresponding clinical information of 168 pancreatic cancer samples from January to December 2021 were downloaded from the Cancer Genome Atlas (TCGA) database, and the data of 179 pancreatic patients from January to December 2021 were downloaded from the GEPIA2 database, and 171 normal pancreatic tissues from TCGA and GTEx databases were simultaneously integrated. The relative expression level of CDCA5 mRNA in pancreatic cancer patients in GEPIA2 database and its relationship with overall survival (OS) and disease-free survival (DFS) were explored. Combined with the clinical data of the patients, univariate and multivariate Cox regression model analysis was used to analyze the factors influencing the OS of pancreatic cancer patients. Gene set enrichment analysis (GSEA) was performed to investigate the possibly involved signal pathways of CDCA5 in pancreatic cancer.Results:In the GEPIA2 database, the relative expression level of CDCA5 mRNA in pancreatic cancer tissues was higher than that in normal pancreatic tissues, and the difference was statistically significant ( P < 0.05). The pancreatic cancer patients were divided into the high CDCA5 mRNA expression group (89 cases) and the low CDCA5 mRNA expression group (89 cases) according to the median of relative expression level of CDCA5 mRNA (the case equal to the median value was not subgrouped). Survival analysis showed that patients with high CDCA5 mRNA expression had shorter OS ( P = 0.024) and DFS ( P = 0.025) compared with those with low CDCA5 mRNA expression. Multivariate Cox analysis showed that in TCGA database, N staging ( HR = 2.15, 95% CI 1.24-3.72, P = 0.006) and CDCA5 expression ( HR = 1.71, 95% CI 1.23-2.38, P = 0.001) were independent influencing factors of OS for pancreatic cancer patients. The results of GSEA enrichment analysis indicated that high CDCA5 mRNA expression was enriched in 13 biological pathways [all P < 0.05, false discovery rate (FDR) < 0.005] including cell cycle, DNA replication, homologous recombination, pyrimidine metabolism, mismatch repair, pentose phosphate pathway, glycolysis gluconeogenesis and p53. The expression of CDCA5 mRNA was positively correlated with the expressions of HK2, PKM, PGK1, ALDOA, EN01 and LDHA (all P < 0.05). Conclusions:CDCA5 is highly expressed in pancreatic cancer tissues and is associated with poor prognosis of patients, and it can be used as a prognostic marker for pancreatic cancer.